Joseph Wolk - Johnson Johnson Chief Financial Officer, Executive Vice President
| JNJ Stock | EUR 147.00 0.18 0.12% |
President
Mr. Joseph J. Wolk is Chief Financial Officer, Executive Vice President of the Company. He was previously Vice President, Group Finance for the Pharmaceuticals Group of Johnson Johnson, where he provided finance leadership, supporting Worldwide Chairman, Pharmaceuticals Joaquin Duato, and Chief Scientific OfficerPaul Stoffels, as a member of the Pharmaceuticals Group Operating Committee. Prior to that role, he held other finance leadership positions at Johnson Johnson as Vice President of Finance for the Medical Devices Global Supply Chain, and as Chief Financial Officer of the North America Pharmaceuticals Group, responsible for Centocor Ortho Biotech Inc. as well as U.S. Pricing Strategy and Compliance. Wolk joined Johnson Johnson in 1998 as a Finance Manager in the OrthoMcNeil Pharmaceutical organization. Prior to joining Johnson Johnson, Wolk held multiple positions of increasing responsibility at Ametek, Inc. He holds a BS degree in Finance from St. Joseph University, where he currently serves on the Haub School of Business Board of Visitors, and he also holds a Juris Doctor degree from Temple University School of Law and is a Certified Public Accountant. since 2018.
| Age | 52 |
| Tenure | 6 years |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| A Washington, Independent Director | ||
| Jennifer Doudna, Independent Director | ||
| Alex Gorsky, Chairman of the Board, Chief Executive Officer | ||
| Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
| Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
| Marillyn Hewson, Independent Director | ||
| Ronald Williams, Independent Director | ||
| Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| Michael Ullmann, Executive Vice President, General Counsel | ||
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
| D Davis, Independent Director | ||
| Hubert Joly, Independent Director | ||
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
| Anne Mulcahy, Lead Independent Director | ||
| Mary Beckerle, Independent Director | ||
| Joseph Wolk, Chief Financial Officer, Executive Vice President | ||
| Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer | ||
| Ian Davis, Independent Director | ||
| Paulus Stoffels, Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group | ||
| Mark McClellan, Independent Director | ||
| Charles Prince, Independent Director | ||
| Peter Fasolo, Chief Human Resource Officer, Executive Vice President | ||
| Mark Weinberger, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 443.95 B | |||
| Price To Book | 6.23 X | |||
| Price To Sales | 4.94 X | |||
| Revenue | 94.94 B | |||
| EBITDA | 28.97 B | |||
| Net Income | 17.94 B | |||
| Total Debt | 26.89 B | |||
| Cash Flow From Operations | 21.19 B | |||
| Price To Earnings To Growth | 3.83 X | |||
| Number Of Employees | 33 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Johnson Stock
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Johnson Stock refer to our How to Trade Johnson Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.